HansBiomed Corporation (KOSDAQ:042520)

Market Cap	108.31B
Revenue (ttm)	80.65B
Net Income (ttm)	-8.04B
Shares Out	12.99M
EPS (ttm)	-620.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,248
Average Volume	14,684
Open	8,030.00
Previous Close	8,130.00
Day's Range	7,970.00 - 8,250.00
52-Week Range	6,500.00 - 16,600.00
Beta	0.68
RSI	48.13
Earnings Date	Feb 12, 2025

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Employees: 127
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In 2024, HansBiomed's revenue was 81.14 billion, an increase of 3.98% compared to the previous year's 78.03 billion. Losses were -7.22 billion, -68.66% less than in 2023.